Eupraxia Pharmaceuticals Announces Data From RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis Consistent improvement in patient report https://www.moomoo.com/t/news/post/43464643/YRmb6ey7ea
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.